Cargando…
Empagliflozin reduces arrhythmogenic effects in rat neonatal and human iPSC-derived cardiomyocytes and improves cytosolic calcium handling at least partially independent of NHE1
The antidiabetic agent class of sodium-glucose cotransporter 2 (SGLT2) inhibitors confer unprecedented cardiovascular benefits beyond glycemic control, including reducing the risk of fatal ventricular arrhythmias. However, the impact of SGLT2 inhibitors on the electrophysiological properties of card...
Autores principales: | Silva dos Santos, Danúbia, Turaça, Lauro Thiago, Coutinho, Keyla Cristiny da Silva, Barbosa, Raiana Andrade Quintanilha, Polidoro, Juliano Zequini, Kasai-Brunswick, Tais Hanae, Campos de Carvalho, Antonio Carlos, Girardi, Adriana Castello Costa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226982/ https://www.ncbi.nlm.nih.gov/pubmed/37248416 http://dx.doi.org/10.1038/s41598-023-35944-5 |
Ejemplares similares
-
The Angiotensin II Type 1 Receptor-Associated Protein Attenuates Angiotensin II-Mediated Inhibition of the Renal Outer Medullary Potassium Channel in Collecting Duct Cells
por: Polidoro, Juliano Zequini, et al.
Publicado: (2021) -
Action potential variability in human pluripotent stem cell-derived cardiomyocytes obtained from healthy donors
por: Carvalho, A. B., et al.
Publicado: (2022) -
Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells
por: Chen, Sha, et al.
Publicado: (2023) -
Modelling premature cardiac aging with induced pluripotent stem cells from a hutchinson-gilford Progeria Syndrome patient
por: Monnerat, Gustavo, et al.
Publicado: (2022) -
Empagliflozin and HFrEF: Known and Possible Benefits of NHE1 Inhibition
por: Jun, Seungho, et al.
Publicado: (2019)